Recent

% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • jgmtruth jgmtruth Oct 15, 2013 12:15 PM Flag

    Gilead idelalisib some safety concerns.

    With idelalisib There were some adverse events during mid-stage studies, however, that could possibly raise some safety concerns. Severe reactions experienced by patients included pneumonia, dehydration, anemia, neutropenia, and thrombocytopenia.IMO ibrutinib much better with no safety issues.

    Sentiment: Strong Buy

 
PCYC
257.100.00(0.00%)Apr 23 3:59 PMEDT